Application note: High-throughput sialylation screening in combination with titer monitoring for expediting clone selection in cell-line development
Glycosylation is one of the most important post-translational modifications when developing new biologics. It has a considerable impact on product performance and variability and is therefore a critical quality attribute (CQA), influencing product safety and efficacy.
Protein glycosylation can affect isolation and purification steps (process consistency), pharmacokinetics (half-life) properties and in vitro stability (product shelf-life). Sialylation is especially important as it significantly affects the safety and efficacy of therapeutic glycoproteins.
Related content from this organisation
- A label-free imaging technique for drug evaluation at single‑cell level
- Bispecific antibodies: the next generation of immuno-oncology drugs
- Oncology meets immunology – antibody-mediated regulation of the immune response
- Antibody therapeutics for COVID-19
- Defusing antibody neutralisers in AAV gene therapy